Should FDA Clearance Of QIAstat-Dx Sepsis Panel Require Action From Qiagen (QGEN) Investors?

In August 2026, Qiagen received FDA clearance for its QIAstat-Dx BCID GPF Plus AMR Panel, expanding rapid diagnostics for bloodstream infections and supporting faster targeted sepsis care in the US. This clearance reinforces the QIAstat-Dx platform as a central growth driver for Qiagen, although competition in the syndromic testing space remains a risk.

This Wire brief sits within Fusion42's coverage of Medtech.